Updated on 25 November 2014
AbbVie has also announced its intention to build a bulk biologics manufacturing facility
Singapore: AbbVie, a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott, has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Singapore's Tuas Biomedical Park.
The facility will expand the company's global operations for small molecule and biologics manufacturing, providing increased capacity for compounds within AbbVie's immunology and oncology pipelines.
"The Singapore site will help to strengthen our global manufacturing capabilities, offering a higher degree of flexibility and scale," said Dr Azita Saleki-Gerhardt, senior vice president, Operations, AbbVie. "The facility will support new technologies and the growth of our pipeline in immunology and oncology, helping us to address significant unmet medical needs for patients around the world."
AbbVie has also announced its intention to build a bulk biologics manufacturing facility expected to be operational in 2019.